Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mônica Barcellos Arruda is active.

Publication


Featured researches published by Mônica Barcellos Arruda.


JAMA Neurology | 2016

Congenital Zika Virus Infection: Beyond Neonatal Microcephaly

Adriana Suely de Oliveira Melo; Renato S. Aguiar; Melania Maria Ramos de Amorim; Mônica Barcellos Arruda; Fabiana O. Melo; Suelem Taís Clementino Ribeiro; Alba Gean Medeiros Batista; Thales Ferreira; Mayra Pereira dos Santos; Virgínia Vilar Sampaio; Sarah Rogéria Martins Moura; Luciana Portela Rabello; Clarissa Emanuelle Gonzaga; G. Malinger; Renato Ximenes; Patricia Soares de Oliveira-Szejnfeld; Fernanda Tovar-Moll; Leila Chimelli; Paola P. Silveira; Rodrigo Delvechio; Luiza M. Higa; Loraine Campanati; Rita Maria Ribeiro Nogueira; Ana Maria Bispo de Filippis; Jacob Szejnfeld; Carolina M. Voloch; Orlando C. Ferreira; Rodrigo M. Brindeiro; Amilcar Tanuri

Importance Recent studies have reported an increase in the number of fetuses and neonates with microcephaly whose mothers were infected with the Zika virus (ZIKV) during pregnancy. To our knowledge, most reports to date have focused on select aspects of the maternal or fetal infection and fetal effects. Objective To describe the prenatal evolution and perinatal outcomes of 11 neonates who had developmental abnormalities and neurological damage associated with ZIKV infection in Brazil. Design, Setting, and Participants We observed 11 infants with congenital ZIKV infection from gestation to 6 months in the state of Paraíba, Brazil. Ten of 11 women included in this study presented with symptoms of ZIKV infection during the first half of pregnancy, and all 11 had laboratory evidence of the infection in several tissues by serology or polymerase chain reaction. Brain damage was confirmed through intrauterine ultrasonography and was complemented by magnetic resonance imaging. Histopathological analysis was performed on the placenta and brain tissue from infants who died. The ZIKV genome was investigated in several tissues and sequenced for further phylogenetic analysis. Main Outcomes and Measures Description of the major lesions caused by ZIKV congenital infection. Results Of the 11 infants, 7 (63.6%) were female, and the median (SD) maternal age at delivery was 25 (6) years. Three of 11 neonates died, giving a perinatal mortality rate of 27.3%. The median (SD) cephalic perimeter at birth was 31 (3) cm, a value lower than the limit to consider a microcephaly case. In all patients, neurological impairments were identified, including microcephaly, a reduction in cerebral volume, ventriculomegaly, cerebellar hypoplasia, lissencephaly with hydrocephalus, and fetal akinesia deformation sequence (ie, arthrogryposis). Results of limited testing for other causes of microcephaly, such as genetic disorders and viral and bacterial infections, were negative, and the ZIKV genome was found in both maternal and neonatal tissues (eg, amniotic fluid, cord blood, placenta, and brain). Phylogenetic analyses showed an intrahost virus variation with some polymorphisms in envelope genes associated with different tissues. Conclusions and Relevance Combined findings from clinical, laboratory, imaging, and pathological examinations provided a more complete picture of the severe damage and developmental abnormalities caused by ZIKV infection than has been previously reported. The term congenital Zika syndrome is preferable to refer to these cases, as microcephaly is just one of the clinical signs of this congenital malformation disorder.


Journal of the International AIDS Society | 2009

Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV

Lilian Amaral Inocencio; Anderson Alvarenga Pereira; Maria Cecilia Araripe Sucupira; José Carlos Couto Fernandez; Célia P Jorge; Denise Fc Souza; Helena T Fink; Ricardo Sobhie Diaz; Irina M Becker; Theodoro A Suffert; Mônica Barcellos Arruda; Olinda Macedo; Mariangela Bg Simão; Amilcar Tanuri

Use of antiretrovirals is widespread in Brazil, where more than 200,000 individuals are under treatment. Although general prevalence of primary antiretroviral resistance in Brazil is low, systematic sampling in large metropolitan areas has not being performed.The HIV Threshold Survey methodology (HIV-THS, WHO) was utilized, targeting Brazils four major regions and selecting the six most populated state capitals: Sao Paulo, Rio de Janeiro, Salvador, Porto Alegre, Brasilia and Belem. We were able to sequence samples from 210 individuals with recent HIV diagnosis, 17 of them (8.1%) carrying HIV isolates with primary antiretroviral resistance mutations. Five, nine and four isolates showed mutations related to resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), respectively. Using HIV-THS, we could find an intermediate level of transmitted resistance (5% to 15%) in Belem/Brasilia, Sao Paulo and Rio de Janeiro. Lower level of transmitted resistance (<5%) were observed in the other areas. Despite the extensive antiretroviral exposure and high rates of virologic antiretroviral failure in Brazil, the general prevalence of primary resistance is still low. However, an intermediate level of primary resistance was found in the four major Brazilian cities, confirming the critical need to start larger sampling surveys to better define the risk factors associated with transmission of resistant HIV.


The Journal of Infectious Diseases | 2005

Low Accumulation of L90M in Protease from Subtype F HIV-1 with Resistance to Protease Inhibitors Is Caused by the L89M Polymorphism

Alexandre R. Calazans; Rodrigo M. Brindeiro; Patrícia A. Brindeiro; Hugo Verli; Mônica Barcellos Arruda; Luis M. F. Gonzalez; Jorge A. Guimarães; Ricardo Sobhie Diaz; Octavio A. C. Antunes; Amilcar Tanuri

BACKGROUND This work evaluates the role of subtype F human immunodeficiency virus type 1 (HIV-1) protease (PR) substitutions L89M and L90M in viral replication and resistance to PR inhibitors (PIs). METHODS Subtype B and F PR genes were subjected to site-directed mutagenesis, to create and reverse the methionine at positions 89 and 90. Viruses were re-created in cell culture, and their replicative capacity was assessed by fitness assay. Generated viruses were also phenotyped for PI resistance. RESULTS The subtype F clone (89M90L) showed a replicative capacity comparable to that of the PI-susceptible subtype B clone (89L90L) and was more fit than the L89M mutated subtype B clone (89M90L). Both 89M90M subtype B and F clones presented the lowest fitness s values. The L89M mutation impacted phenotypic resistance to all PIs in half of the subtype F isolates but not in the subtype B isolates. Subtype F isolates presented a phenotypic profile similar to that of subtype B isolates when the M89L mutation was introduced. CONCLUSION The L89M mutation in subtype F viruses is a high genetic barrier to the accumulation of the L90M resistance mutation and can function as a resistance mutation, depending on the presence of other polymorphisms in the subtype F PR backbone.


Infection, Genetics and Evolution | 2009

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure

Ana T. Dumans; Claudia C. Barreto; André F. Santos; Mônica Barcellos Arruda; Thatiana M. Sousa; Elizabeth S. Machado; Ester C. Sabino; Rodrigo M. Brindeiro; Amilcar Tanuri; Alberto José da Silva Duarte; Marcelo A. Soares

The goal of this work was to compare the differences between human immunodeficiency virus type 1 (HIV-1) of B and F1 subtypes in the acquisition of major and minor protease inhibitor (PI)-associated resistance mutations and of other polymorphisms at the protease (PR) gene, through a cross sectional study. PR sequences from subtypes B and F1 isolates matched according to PI exposure time from Brazilian patients were included in this study. Sequences were separated in four groups: 24 and 90 from children and 141 and 99 from adults infected with isolates of subtypes F1 and B, respectively. For comparison, 211 subtype B and 79 subtype F1 PR sequences from drug-naïve individuals were included. Demographic and clinical data were similar among B- and F1-infected patients. In untreated patients, mutations L10V, K20R, and M36I were more frequent in subtype F1, while L63P, A71T, and V77I were more prevalent in subtype B. In treated patients, K20M, D30N, G73S, I84V, and L90M, were more prevalent in subtype B, and K20T and N88S were more prevalent in subtype F1. A higher proportion of subtype F1 than of subtype B strains containing other polymorphisms was observed. V82L mutation was present with increased frequency in isolates from children compared to isolates from adults infected with both subtypes. We could observe a faster resistance emergence in children than in adults, during treatment with protease inhibitors. This data provided evidence that, although rates of overall drug resistance do not differ between subtypes B and F1, the former accumulates resistance at higher proportion in specific amino acid positions of protease when compared to the latter.


Archives of Virology | 2008

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique.

Celina Monteiro Abreu; Patrícia A. Brindeiro; Angelica N. Martins; Mônica Barcellos Arruda; Emilio Bule; Sergio Stakteas; Amilcar Tanuri; Rodrigo M. Brindeiro

This work evaluated HIV-1 subtypes from different geographic regions and phenotypic data from drug-naïve HIV-positive pregnant women from Mozambique. We analyzed 75 pol sequences from patients and the distribution of the subtypes in three regions of Mozambique and found that the majority of samples analyzed clustered with subtype C. In the northern region, multiple variants were found 5 (~18%) subtype A, 3 (~11%) subtype D and 2 (~7.1%) mosaics (A/C/D and C/D), whereas 18 (64.3%) isolates were subtype C, from a total of 28 samples. Already in the southern region, only one (5%) isolate of 20 samples was subtype D, and the other 19 (95%) isolates were subtype C. All 27 (100%) isolates from the central region grouped within clade C. No primary resistance mutations to IP, NNRTI or NRTI were found. There was no evidence of phenotypic resistance in any of the isolates tested, suggesting that neither the polymorphism in the protease, nor the one found at codon 215 of the RT gene caused an increase in phenotypic resistance. This finding suggests that HAART regimens indicated by WHO will probably be successful in Mozambique.


AIDS Research and Human Retroviruses | 2009

Enfuvirtide (T-20) Resistance-Related Mutations in HIV Type 1 Subtypes B, C, and F Isolates from Brazilian Patients Failing HAART

A.C.A. Oliveira; Angelica N. Martins; Ana Flavia Nacif P Coelho Pires; Mônica Barcellos Arruda; Amilcar Tanuri; H.S. Pereira; Rodrigo M. Brindeiro

The synthetic peptide T-20 (enfuvirtide, EFV) represents the first compound approved by the FDA known as entry inhibitors (EIs). The resistance mutations associated with this new class of antiretroviral drug are located in the first heptad repeat (HR1) region of gp41. Amino acid changes in codons G36D/S, I37V, V38A/M/E, Q39H/R, Q40H, N42T, and N43D can confer resistance to EFV. In this work we investigated the presence of resistance mutations that occur in patients never treated with EFV and failing HAART with protease inhibitors (PIs), nucleoside reverse transcriptase (RT) inhibitors (NRTIs), and nonnucleoside RT inhibitors (NNRTIs). This knowledge can reveal whether this salvage therapy can be effective in patients failing HAART. For this, we amplified 65 samples from plasma isolates and than sequenced a fragment of 416 nt encompassing the HR1 and HR2 regions (amino acids 33-170 of gp41). The subtype distribution among the 65 isolates was 45 (69.23%) subtype B, 9 (13.85%) subtype C, 7 (10.77%) subtype F1, and 4 (6.15%) mosaics B/F1, B/C, F1/C, and C/F1/B. We found a high prevalence (7.6%) of EFV-associated mutation G36D in this cohort of patients failing HAART therapy, five isolates from subtype B (11.11% within this group). In contrast, when 1079 sequences from drug-naive patients were analyzed, only one showed the G36D substitution. This finding indicates a strong association between the selected position G36D and HAART therapy (p < 0.0001). The isolates that possess these mutations can develop resistance to EFV more rapidly. Nevertheless, more information about the impact of these mutations in salvage therapy with EFV in patients failing HAART must still be obtained.


The Journal of Rheumatology | 2017

Zika Virus in the Joint of a Patient with Rheumatoid Arthritis.

Luis Roimicher; Orlando C. Ferreira; Mônica Barcellos Arruda; Amilcar Tanuri

To the Editor: Since 2015, Brazil has experienced a major public health crisis caused by the arboviruses Zika (ZIKV) and Chikungunya (CHIKV), which are circulating along with the dengue virus1. ZIKV is now considered endemic in all Brazilian states and is currently spreading widely in South and Central America and is threatening the United States and Europe2,3. ZIKV and CHIKV share similar acute clinical presentation with arthralgia, skin rash, and fever, which also resembles other rheumatic diseases1,4. Most relevantly, ZIKV and CHIKV may complicate the clinical condition of rheumatic patients. We share here the case of a 53-year-old woman with a … Address correspondence to Dr. L. Roimicher, Department of Rheumatology–Internal Medicine, Hospital Universitario CFF, Universidade Federal do Rio de Janeiro, Rua Prof Rodolpho Paulo Rocco 255, 70 Andar, Rio de Janeiro, Brazil. E-mail: mail-luizroimicher{at}gmail.com


Journal of Medical Systems | 2016

Lopinavir Resistance Classification with Imbalanced Data Using Probabilistic Neural Networks

Letícia Martins Raposo; Mônica Barcellos Arruda; Rodrigo M. Brindeiro; Flávio Fonseca Nobre

Resistance to antiretroviral drugs has been a major obstacle for long-lasting treatment of HIV-infected patients. The development of models to predict drug resistance is recognized as useful for helping the decision of the best therapy for each HIV+ individual. The aim of this study was to develop classifiers for predicting resistance to the HIV protease inhibitor lopinavir using a probabilistic neural network (PNN). The data were provided by the Molecular Virology Laboratory of the Health Sciences Center, Federal University of Rio de Janeiro (CCS-UFRJ/Brazil). Using bootstrap and stepwise techniques, ten features were selected by logistic regression (LR) to be used as inputs to the network. Bootstrap and cross-validation were used to define the smoothing parameter of the PNN networks. Four balanced models were designed and evaluated using a separate test set. The accuracies of the classifiers with the test set ranged from 0.89 to 0.94, and the area under the receiver operating characteristic (ROC) curve (AUC) ranged from 0.96 to 0.97. The sensitivity ranged from 0.94 to 1.00, and the specificity was between 0.88 and 0.92. Four classifiers showed performances very close to three existing expert-based interpretation systems, the HIVdb, the Rega and the ANRS algorithms, and to a k-Nearest Neighbor.


PLOS ONE | 2018

Pregnant women co-infected with HIV and Zika: Outcomes and birth defects in infants according to maternal symptomatology

Esau Joao; Orlando C. Ferreira; Maria Isabel Gouvea; Maria de Lourdes Benamor Teixeira; Amilcar Tanuri; Luiza M. Higa; Deise A. Costa; Ronaldo Mohana-Borges; Mônica Barcellos Arruda; Haroldo José de Matos; Maria Letícia Santos Cruz; Wallace Mendes-Silva; Jennifer S. Read

Background Zika virus (ZIKV) was first isolated in Uganda in 1947. In Brazil, the first reported case of ZIKV infection was in May 2015. Additionally, dengue (DENV) is endemic and there has been a recent outbreak of chikungunya (CHIKV). Since the clinical manifestations of different arboviral infections (AI) can be similar, definitive diagnosis requires laboratory testing. Objectives To determine the prevalence of ZIKV, DENV, and CHIKV infections in a Brazilian cohort of HIV-infected pregnant women, to assess clinical/immunological characteristics and pregnancy outcomes of women with evidence of recent AI. Study design Laboratory diagnosis of ZIKV, DENV and CHIKV infections utilized serological assays, RT-PCR and PRNT. The tests were performed at the first visit, 34–36 weeks of gestation and at any time if a woman had symptoms suggestive of AI. Mann-Whitney tests were used for comparison of medians, Chi-square or Fisher’s to compare proportions; p< 0.05 was considered statistically significant. Poisson regression was used to analyze risk factors for central nervous system (CNS) malformations in the infant according to maternal symptomatology. Results Of 219 HIV-infected pregnant women enrolled, 92% were DENV IgG+; 47(22%) had laboratory evidence of recent AI. Of these, 34 (72%) were ZIKV+, nine (19%) CHIKV+, and two (4%) DENV+. Symptoms consistent with AI were observed in 23 (10%) women, of whom 10 (43%) were ZIKV+, eight (35%) CHIKV+. No CNS abnormalities were observed among infants of DENV+ or CHIKV+ women; four infants with CNS abnormalities were born to ZIKV+ women (three symptomatic). Infants born to ZIKV+ women had a higher risk of CNS malformations if the mother was symptomatic (RR = 7.20), albeit not statistically significant (p = 0.066). Conclusions Among HIV-infected pregnant women with laboratory evidence of a recent AI, 72% were ZIKV-infected. In this cohort, CNS malformations occurred among infants born to both symptomatic and asymptomatic pregnant women with Zika infection.


Frontiers of Medicine in China | 2018

Prevalence of IgG Autoantibodies against GD3 Ganglioside in Acute Zika Virus Infection

Dirlei Nico; Luciana Conde; Juan Rivera-Correa; Andréia Vasconcelos dos Santos; Louise A. Mesentier-Louro; Leonardo Freire de Lima; Mônica Barcellos Arruda; Celio Geraldo Freire de Lima; Orlando C. Ferreira; Maria Elisabeth Lopes Moreira; Andrea Zin; Zilton Vasconcelos; Rosalia Mendez Otero; Clarisa Beatriz Palatnik de Sousa; Amilcar Tanuri; Adriane R. Todeschini; Wilson Savino; Ana Rodriguez; Alexandre Morrot

Zika virus (ZIKV) disease has become a global health emergency with devastating effects on public health. Recent evidences implicate the virus as an emergent neuropathological agent promoting serious pathologies of the human nervous system, that include destructive and malformation consequences such as development of ocular and fetal brain lesions, microcephaly in neonates, and Guillain–Barré syndrome (GBS) in adults. These neurological disorders of both central and peripheral nervous systems are thought to be associated to the neurotropic properties of the virus that has ability to infect neural stem cells as well as peripheral neurons, a hallmark of its pathogenicity. The presence of autoantibodies against gangliosides plays a pivotal role in the etiogenesis of GBS and a variety of neurological disorders. Gangliosides are a class of galactose-containing cerebrosides mainly expressed in nervous system tissues playing a critical role in the physiology of neural cells and neurogenesis. Herein, our findings indicate that patients at acute phase of ZIKV infection without any neurological signs show increased levels of IgG autoantibody against GD3 gangliosides, a class of glycolipid found to be highly expressed in neural stem cell acting in the maintenance of their self-renewal cellular capacity. It is possible that a pathological threshold of these antibodies is only acquired in secondary or subsequent infections. In the light of these evidences, we propose that the target of GD3 by autoimmune responses may possibly has an effect in the neuropathy and neurogenesis disorder seen during ZIKV infection.

Collaboration


Dive into the Mônica Barcellos Arruda's collaboration.

Top Co-Authors

Avatar

Amilcar Tanuri

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Rodrigo M. Brindeiro

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Orlando C. Ferreira

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Angelica N. Martins

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Luiza M. Higa

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Patrícia A. Brindeiro

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Renato S. Aguiar

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Ricardo Sobhie Diaz

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Adriana Suely de Oliveira Melo

Federal University of Campina Grande

View shared research outputs
Top Co-Authors

Avatar

Carolina M. Voloch

Federal University of Rio de Janeiro

View shared research outputs
Researchain Logo
Decentralizing Knowledge